Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Adalimumab for Dupuytren's disease	Adalimumab	Dupuytren's disease	Musculoskeletal System	2023	View \| Download
Adagrasib for previously treated KRAS G12C mutated advanced non-small-cell lung cancer	Adagrasib (MRTX-849)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Acoramidis for symptomatic transthyretin amyloid cardiomyopathy	Acoramidis (AG10)	Transthyretin amyloid cardiomyopathy	Cardiovascular System	2023	View \| Download
Acarizax for treating allergic rhinitis or allergic rhinoconjunctivitis in children aged 5 to 11 years old	Acarizax	Allergic rhinitis , Allergic rhinoconjunctivitis	Immunology , Ophthalmology	2024	View \| Download
Acalabrutinib with venetoclax for previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma	Acalabrutinib (Calquence; ACP-196) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL) , Small lymphocytic lymphoma (SLL)	Haematological Cancer and Lymphomas	2022	View \| Download
Acalabrutinib with venetoclax and obinutuzumab for treating previously untreated chronic lymphocytic leukaemia	Acalabrutinib (Calquence; ACP-196) , Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2022	View \| Download
Acalabrutinib with bendamustine and rituximab for treating previously untreated mantle cell lymphoma	Acalabrutinib (Calquence; ACP-196) , Bendamustine (Treanda; EP-3102; Levact; Ribomustin; bendamustine hydrochloride monohydrate; bendamustine hydrochloride) , Rituximab (MabThera; Rituxan; RG 105)	Mantle cell lymphoma	Haematological Cancer and Lymphomas	2022	View \| Download
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma	Acalabrutinib (Calquence; ACP-196)	Mantle cell lymphoma	Haematological Cancer and Lymphomas	2023	View \| Download
Acalabrutinib for relapsed/refractory Chronic lymphocytic leukaemia	Acalabrutinib (Calquence; ACP-196)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2019	View \| Download
Acalabrutinib for chronic lymphocytic leukaemia – first line	Acalabrutinib (Calquence; ACP-196)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2019	View \| Download